However, increased growth hormone activity may carry risks such as: insulin resistance fluid retention and joint swelling cardiovascular complications abnormal tissue growth Human orthopaedic evidence remains limited, and most musculoskeletal data are still preclinical
Common issues people experience include nausea, vomiting, diarrhea, and constipation
[20] As a pharmacist, I can appreciate why such a profile has made this drug the next blockbuster
The complaints allege that Lemmes studies do not actually demonstrate any discernable effect on weight loss, and the results measured by the studies are negligible compared to the naturally occurring fluctuations in the bodys GLP-1 levels after activities such as eating
Phase Weeks 1-2 Draw volume 7.5 units (0.075 mL) Total blend delivered ~2.0 mg total blend GHK-Cu ~1.25 mg KPV ~250 mcg BPC-157 ~250 mcg TB-500 ~250 mcg Phase Weeks 3-4 Draw volume 15 units (0.15 mL) Total blend delivered ~4.0 mg total blend GHK-Cu ~2.5 mg KPV ~500 mcg BPC-157 ~500 mcg TB-500 ~500 mcg Phase Weeks 5-8 Draw volume 22.5 units (0.225 mL) Total blend delivered ~6.0 mg total blend GHK-Cu ~3.75 mg KPV ~750 mcg BPC-157 ~750 mcg TB-500 ~750 mcg Phase Weeks 9-12 (taper) Draw volume 15 units (0.15 mL) Total blend delivered ~4.0 mg total blend GHK-Cu ~2.5 mg KPV ~500 mcg BPC-157 ~500 mcg TB-500 ~500 mcg Blend ratio 50 / 10 / 10 / 10 mg GHK-Cu dominant Select a draw volume from the titration table above to see the approximate amount of each peptide delivered
